Investigating the role of vitamin E and metformin in improving fatty liver

Not Applicable

Recruiting

Conditions: Fatty liver.
Fatty (change of) liver, not elsewhere classified

Registration Number: IRCT2017061334514N1

Lead Sponsor: Qazvin University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 200

Inclusion Criteria

The aim of this study will be to determine the effect of vitamin E and metformin on improvement children with nonalcoholic fatty liver disease.
Inclusion criteria include:
1-Age 8 to 14 years
2-Body mass index above 95 percent,
3-The risk of non-alcoholic fatty liver.
Exclusion criteria include:
1-Patients suffering from diabetes or pre-diabetes patient
2-BMI below 95 percent
3-History of alcohol use
4-The risk of obesity-related diseases such as hereditary syndrome, Prader Willi;
5-Pathological obesity cushingoid such as syndrome, hypothyroidism, Hypo Pseudo hyperparathyroidism
6-The risk of chronic diseases such as kidney or liver cirrhosis, viral hepatitis;
7-Lack of parental consent to participate in the study.

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fasting blood glucose. Timepoint: Before treatment and at the second and fourth month of treatment. Method of measurement: Standard protocol.;Lipid profile. Timepoint: Before treatment and at the second and fourth month of treatment. Method of measurement: Standard protocol.;Body mass index. Timepoint: Before treatment and at the second and fourth month of treatment. Method of measurement: Standard protocol.;Levels of fasting insulin. Timepoint: Before treatment and at the second and fourth month of treatment. Method of measurement: Standard protocol.;Insulin sensitivity. Timepoint: Before treatment and at the second and fourth month of treatment. Method of measurement: Standard protocol.;Alanine aminotransferase. Timepoint: Before treatment and at the second and fourth month of treatment. Method of measurement: Standard protocol.;Aspartate aminotransferase. Timepoint: Before treatment and at the second and fourth month of treatment. Method of measurement: Standard protocol.

Secondary Outcome Measures